We took advantage of Elevance Health's share price weakness in the fourth quarter and added modestly to our investment. Click ...

In a report released today, Stephen Baxter from Wells Fargo maintained a Buy rating on Elevance Health (ELV – Research Report), with a price ...

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $492.5, with a ...

StockNews.com cut shares of Elevance Health (NYSE:ELV – Free Report) from a buy rating to a hold rating in a research note ...

Investment analysts at Leerink Partnrs dropped their Q3 2025 EPS estimates for shares of Elevance Health in a research note ...

Shares of Elevance Health Inc. ELV slipped 1.42% to $405.40 Tuesday, on what proved to be an all-around great trading session ...

Before making this announcement, Elevance Health was easily earning enough to cover the dividend. As a result, a large proportion of what it earned was being reinvested back into the business.

Elevance Health Inc. closed 27.50% below its 52-week high of $567.26, which the company achieved on September 3rd.

Analysts' ratings for Elevance Health (NYSE:ELV) over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below illustrates ...

Unless the payments are sustainable, the dividend yield doesn't mean too much. Before making this announcement, Elevance Health was easily earning enough to cover the dividend. As a result, a large ...